MOR
MorphoSys AG Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website morphosys.com
- Employees(FY) 544
- ISIN US6177602025
Performance
+3.16%
1W
-0.72%
1M
+5.65%
3M
+119.56%
6M
+81.41%
YTD
+216.75%
1Y
Profile
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Investment Analysis Report: MOR
Overview
In this investment analysis report, we will delve into a comprehensive analysis of MOR, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, ...
Technical Analysis of MOR 2024-05-03
Overview:
In analyzing the technical indicators for MOR stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potentia...
Recent News & Updates
- 2024-04-29 19:52
- 2024-04-29 16:01
MorphoSys AG Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-04-29 04:01
- 2024-04-24 11:00
- 2024-04-23 23:00
- 2024-04-22 22:12
- 2024-04-11 18:26
- 2024-04-11 09:00
- 2024-04-11 08:39
- 2024-04-10 21:00
- 2024-04-02 20:48
- 2024-03-30 03:52
11 Oversold Blue Chip Stocks to Buy Right Now(Insidermonkey)
- 2024-03-22 02:50
- 2024-03-21 14:50
- 2024-03-14 22:37
MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript(Insidermonkey)
- 2024-03-13 16:02
- 2024-03-13 04:02
- 2024-03-11 00:44
20 Highest Paying Countries for Biotechnology(Insidermonkey)
- 2024-03-07 16:15
- 2024-03-07 03:15
- 2024-03-04 13:56
13 Best Pharma Dividend Stocks To Buy in 2024(Insidermonkey)
- 2024-03-03 23:00
- 2024-02-15 14:55
5 Top Performing European Stocks So Far in 2024(Insidermonkey)
- 2024-02-14 23:00
- 2024-02-05 21:29
- 2024-02-05 17:30
Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H(The Wall Street Journal)
- 2024-02-05 17:15
- 2024-02-05 04:44
- 2024-02-05 04:15
- 2024-02-05 04:15
Page 1 of 5
previousnext